Clinical Trials Showing Heightened Heart Attack Risks Spark Concern After Invokana Lawsuit Filings

March 22, 2016 – – TheProductLawyers.com reports on results of clinical trials which now concern many. The trials were conducted on type-2 diabetes drug Invokana, which was released to the market in 2013 after gaining approval from the U.S. Food and Drug Administration. Results of clinical trials done on the new-generation drug have shown a significantly heightened risk of heart attacks among patients taking the drug during the initial 30 days of their treatment.

Invokana was the first of several new-generation diabetes drugs which were released to market called SGLT2 class inhibitors. When clinical trials were done on Invokana, however, the results highlighted an alarming discovery: several patients using the drug suddenly suffered from heart attacks or strokes within the first 30 days of their treatment. After the 30-day period had passed, the risk factors suddenly and unexplainably leveled out. Researchers were unable to pinpoint why this was the case, although it has been established for quite some time now that diabetes drugs can increase cholesterol levels in patients, which can in turn cause heart problems.

Despite the fact that the FDA recently issued a public safety warning regarding Invokana, and has also required manufacturer Janssen Pharmaceuticals (a subdivision of Johnson & Johnson corporation) to make certain changes to the drug’s warning label, they have not yet publicly addressed the possibility of increased heart attack risks for users. The New York Times brought up this issue in a recent article which stated, “The label of the drug includes no warnings about heart attacks or strokes. …The FDA is requiring Johnson & Johnson to conduct five post-marketing studies, including a clinical trial to determine more definitively if the drug increases those risks.”

While patients and the general public alike anxiously await results from these valuable post-market studies, medical professionals have also become concerned and are asking that all patients using Invokana or similar SGLT2 class inhibitor drugs please be aware of and watch for any symptoms of oncoming heart attacks, which can include arm, jaw, neck, chest, and shoulder pain, dizziness, nausea and vomiting, increased fatigue and sweating, or difficulty breathing. Patients taking the drug are asked to remain hyper-vigilant while looking for symptoms within the initial 30 days of treatment, due to the clinical study results which highlighted this as a potentially high-risk time. Patients experiencing even one or two of these symptoms are asked to seek prompt medical attention.

The attorneys of Banville Law are dedicated to keeping the public informed of important information released regarding Invokana and other similar drugs. To help accomplish this, they sponsor TheProductLawyers.com, a resource website which is filled with current and important information for patients. In addition, they are now working to ensure that anyone who has taken Invokana or a similar SGLT2 class inhibitor drug and who has suffered from health problems that they believe were caused by the drug will be given the critical opportunity to evaluate their legal rights fully. Affected individuals could be entitled to substantial compensation. To assist patients looking to pursue justice, the attorneys of Banville Law are offering complimentary legal consultations at this time.

To request more information, or to ask questions, please contact Banville Law by calling 877-671-6480.

###

Contact TheProductLawyers.com:

Banville Law
877-671-6480
info@banvillelaw.com
165 West End Ave #1h,
New York, NY 10023

ReleaseID: 60008818